E2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer.
Cohen S, Feng Y, Catalano P, Mitchell E, O'Dwyer P, Lubner S, Fisher G, Mulcahy M, Burtness B, Benson A. E2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer. Journal Of Clinical Oncology 2014, 32: 4020-4020. DOI: 10.1200/jco.2014.32.15_suppl.4020.Peer-Reviewed Original Research